Skip to main content

Peer Review reports

From: Optimal designs for phase II/III drug development programs including methods for discounting of phase II results

Original Submission
21 Feb 2020 Submitted Original manuscript
2 Mar 2020 Author responded Author comments - Stella Erdmann
Resubmission - Version 2
2 Mar 2020 Submitted Manuscript version 2
10 Mar 2020 Author responded Author comments - Stella Erdmann
Resubmission - Version 3
10 Mar 2020 Submitted Manuscript version 3
24 Apr 2020 Reviewed Reviewer Report - Mauro Gasparini
18 May 2020 Reviewed Reviewer Report
3 Jul 2020 Author responded Author comments - Stella Erdmann
Resubmission - Version 4
3 Jul 2020 Submitted Manuscript version 4
13 Jul 2020 Reviewed Reviewer Report - Mauro Gasparini
21 Jul 2020 Reviewed Reviewer Report
29 Jul 2020 Author responded Author comments - Stella Erdmann
Resubmission - Version 5
29 Jul 2020 Submitted Manuscript version 5
31 Jul 2020 Author responded Author comments - Stella Erdmann
Resubmission - Version 6
31 Jul 2020 Submitted Manuscript version 6
Publishing
3 Aug 2020 Editorially accepted
9 Oct 2020 Article published 10.1186/s12874-020-01093-w

You can find further information about peer review here.

Back to article page